{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:12Z","timestamp":1793228412966,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Applied basic research program of Science and Technology Department of Liaoning Province","award":["2023JH2\/101300036"],"award-info":[{"award-number":["2023JH2\/101300036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83630-x","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T12:43:28Z","timestamp":1737031408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast"],"prefix":"10.1038","volume":"15","author":[{"given":"Qianru","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"6","key":"83630_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian, D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin. Oncol. 43 (6), 676\u2013681 (2016).","journal-title":"Semin. Oncol."},{"issue":"10272","key":"83630_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet (London England). 397 (10272), 410\u2013427 (2021).","journal-title":"Lancet (London England)"},{"issue":"1","key":"83630_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11548-019-02015-y","volume":"15","author":"L Morvan","year":"2020","unstructured":"Morvan, L. et al. Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. Int. J. Comput. Assist. Radiol. Surg. 15 (1), 129\u2013139 (2020).","journal-title":"Int. J. Comput. Assist. Radiol. Surg."},{"issue":"9","key":"83630_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99 (9), 1802\u20131824 (2024).","journal-title":"Am. J. Hematol."},{"issue":"2","key":"83630_CR5","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh, D. et al. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health. 11 (2), e197\u2013e206 (2023).","journal-title":"Lancet Global Health"},{"issue":"5","key":"83630_CR6","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","volume":"18","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti, A. et al. Anti CD38 monoclonal antibodies for multiple myeloma treatment. Hum. Vaccines Immunother. 18 (5), 2052658 (2022).","journal-title":"Hum. Vaccines Immunother."},{"issue":"10","key":"83630_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2021.57.10.3313853","volume":"57","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith, S. R., Foley, N. & Schroeder, M. A. Daratumumab for the treatment of multiple myeloma. Drugs of today (Barcelona, Spain: 1998) 57 (10), 591\u2013605 (2021).","journal-title":"Drugs of today (Barcelona, Spain: 1998)"},{"issue":"26","key":"83630_CR8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33 (26), 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"83630_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.13840","volume":"109","author":"CY Soekojo","year":"2022","unstructured":"Soekojo, C. Y. & Chng, W. J. Treatment horizon in multiple myeloma. Eur. J. Haematol. 109 (5), 425\u2013440 (2022).","journal-title":"Eur. J. Haematol."},{"issue":"10258","key":"83630_CR10","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S0140-6736(20)30977-6","volume":"396","author":"Global age-sex","year":"2020","unstructured":"Global age-sex. -specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950\u20132019: A comprehensive demographic analysis for the global burden of Disease Study 2019. Lancet (London England). 396 (10258), 1160\u20131203 (2020).","journal-title":"Lancet (London England)"},{"issue":"10258","key":"83630_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJ Murray","year":"2020","unstructured":"Murray, C. J. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England) 396 (10258), 1223-1249 (2020).","journal-title":"Lancet (London, England)"},{"issue":"4","key":"83630_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","volume":"70","author":"Z Liu","year":"2019","unstructured":"Liu, Z. et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the global burden of Disease Study 2016 and implications for liver cancer prevention. J. Hepatol. 70 (4), 674\u2013683 (2019).","journal-title":"J. Hepatol."},{"issue":"1","key":"83630_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1186\/s12889-021-11401-8","volume":"21","author":"M Guo","year":"2021","unstructured":"Guo, M., Xu, J. & Du, J. Trends in cervical cancer mortality in China from 1989 to 2018: An age-period-cohort study and join-point analysis. BMC Public. Health. 21 (1), 1329 (2021).","journal-title":"BMC Public. Health"},{"key":"83630_CR14","doi-asserted-by":"publisher","first-page":"102382","DOI":"10.1016\/j.arr.2024.102382","volume":"99","author":"F Cao","year":"2024","unstructured":"Cao, F. et al. Trends and cross-country inequalities in the global burden of osteoarthritis, 1990\u20132019: A population-based study. Ageing Res. Rev. 99, 102382 (2024).","journal-title":"Ageing Res. Rev."},{"issue":"6","key":"83630_CR15","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s13524-013-0243-z","volume":"50","author":"L Luo","year":"2013","unstructured":"Luo, L. Assessing validity and application scope of the intrinsic estimator approach to the age-period-cohort problem. Demography 50 (6), 1945\u20131967 (2013).","journal-title":"Demography"},{"issue":"1","key":"83630_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13524-014-0360-3","volume":"52","author":"B Pelzer","year":"2015","unstructured":"Pelzer, B., te Grotenhuis, M., Eisinga, R. & Schmidt-Catran, A. W. The non-uniqueness property of the intrinsic estimator in annual percent change models. Demography 52 (1), 315\u2013327 (2015).","journal-title":"Demography"},{"issue":"3","key":"83630_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie, Y. et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 94 (3), 567\u2013581 (2018).","journal-title":"Kidney Int."},{"issue":"6","key":"83630_CR18","doi-asserted-by":"publisher","first-page":"103326","DOI":"10.1016\/j.autrev.2023.103326","volume":"22","author":"F Cao","year":"2023","unstructured":"Cao, F. et al. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019. Autoimmun. rev. 22 (6), 103326 (2023).","journal-title":"Autoimmun. rev."},{"issue":"20","key":"83630_CR19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration","year":"2013","unstructured":"World Medical Association Declaration. Of Helsinki: Ethical principles for medical research involving human subjects. Jama 310 (20), 2191\u20132194 (2013).","journal-title":"Jama"},{"issue":"10292","key":"83630_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau, P. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet (London England). 397 (10292), 2361\u20132371 (2021).","journal-title":"Lancet (London England)"},{"issue":"8","key":"83630_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood 136 (8), 936\u2013945 (2020).","journal-title":"Blood"},{"issue":"9","key":"83630_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat. Med. 29 (9), 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"issue":"9","key":"83630_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: A systematic analysis for the global burden of Disease Study 2016. JAMA Oncol. 4 (9), 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"issue":"5","key":"83630_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. Jama 327 (5), 464\u2013477 (2022).","journal-title":"Jama"},{"issue":"1","key":"83630_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: An analysis of the global burden of Disease Study 2016. J. Hematol. Oncol. 12 (1), 136 (2019).","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"83630_CR26","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1016\/j.clml.2023.08.008","volume":"23","author":"H Gasoyan","year":"2023","unstructured":"Gasoyan, H. et al. Disparities in multiple myeloma treatment patterns in the United States: A systematic review. Clin. Lymphoma Myeloma Leuk. 23 (11), e420\u2013e7 (2023).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"83630_CR27","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15 (12), e538\u2013e548 (2014).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83630-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T12:43:33Z","timestamp":1737031413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83630-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83630"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83630-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5309684\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article uses the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 public database and does not require ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"2204"}}